摘要
PBD1是位于PLK1 C端一处的特征性结构域,具有调节酶的催化活性和亚细胞动态定位的重要功能。目前大部分抗肿瘤PLK1抑制剂均针对ATP结合口袋,但ATP结合区结构保守性使得对靶标的选择性难以实现,而且还易与其他激酶抑制剂类药物产生交叉耐药性。而远离PLK1催化区域的PBD1因其结构特异性而在近期受到广泛关注,有望成为激酶结构域的替代靶点。研究者从化学小分子或多肽入手,期望开发出有效的PBD1抑制剂,用于抗肿瘤药物研究。本文对PBD1的结构和功能以及主要抑制剂的研究进展进行了综述和展望。
Polo-box domain 1 （PBD1） is a characteristic domain of polo-like kinase 1 （PLK1）, which locates in C-terminal and can influence the catalytic activity and specific subcellular locations of PLK1. At present, most PLK1 inhibitors are developed to occupy the ATP pocket or its close sites. However, this kind of PLK1 inhibitors is difficult to pursue target selectivity and may encounter cross drug resistance with other kinase inhibitors due to the conserved sequence of ATP pocket. Recently, PBD 1, with aberrant specificity in sequence and structure, has attracted enormous interests as the alternative target to the discovery of corresponding inhibitors for anti-tumor drugs. The structure and function of PBD1 as well as the advances of its inhibitors are reviewed in this paper.
出处
《药学学报》
CAS
CSCD
北大核心
2013年第3期315-324,共10页
Acta Pharmaceutica Sinica
基金
国家自然科学基金资助项目(21102181)
